# ELOQUENT-3 (NCT02654132)

> An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

No report yet. It can be ordered.

- Drugs tested: elotuzumab
- Indication: relapsed and refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02654132
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Multiple Myeloma
- Interventions: Elotuzumab; Pomalidomide; Dexamethasone
- Enrollment: 117
- Primary outcome: Progression Free Survival (PFS)

## Some of the questions raised in the 19 most recent indexed sources

_Automated from the 19 newest of 22 indexed sources (Aug 2018 – Apr 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether elotuzumab-pomalidomide-dexamethasone retains a role after daratumumab or other anti-CD38 exposure or refractoriness
- How to interpret the overall survival analysis of elotuzumab plus pomalidomide-dexamethasone
- Whether pomalidomide-dexamethasone remains an appropriate control arm, and how it performed versus other trials
- Whether elotuzumab-pomalidomide-dexamethasone can be compared across trials with daratumumab- or isatuximab-pomalidomide-dexamethasone

## Indexed commentary on ELOQUENT-3 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 18 posts on X
- 2 YouTube videos
- 2 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=eloquent-3-nct02654132

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02654132", "email": "<work email>"}; the inbox owner confirms by the emailed link.
